BridgeMD
New treatment option for Chronic Coronary Syndrome
Official title Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome
ClinicalTrials.gov ID: NCT06896708
What this study is testing
What is Intensive lipid-lowering strategy?
Intensive lipid-lowering strategy is an investigational medicine, being studied as a potential treatment for chronic coronary syndrome.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a multicenter, open-label, parallel-group, randomized trial to determine if intensive lipid-lowering therapy (goal for LDL-C \<1.0 mmol/L and ≥50% reduction frome baseline) could delay progression of coronary atherosclerotic obstructive leisions compared with guideline recommended lipid-lowering therapy (goal for LDL-C \<1.8 mmol/L and ≥50% reduction frome baseline) among participants between 18-60 years old with non-invasively managed chronic coronary syndrome (at least one lesion with a 50%-70% stenosis).
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 60
You may be able to join if
- 1\. Aged 18-60 years at screening 2. Stable angina symptoms with suspected or confirmed coronary artery disease; 2. CCTA examination demonstrating...
- 3\. people who have been using statin therapy alone for at least 4 weeks prior to enrollment with a baseline LDL-C ≥1.8mmol/L or people who have not...
You likely can't join if
- Left main coronary artery disease or severe three-vessel disease;
- Ultra-high-risk ASCVD patients: ≥2 severe ASCVD events or 1 severe ASCVD event with ≥2 high-risk factors;
- Use of PCSK9 inhibitors or ezetimibe within 8 weeks prior to study enrollment;
- The baseline LDL-C was relatively high (LDL-C≥2.6 mmol/L in those taking statins and ≥4.9 mmol/L in those not taking statins).
- Familial hypercholesterolemia;
- Known allergy/intolerance to lipid-lowering drugs used in the trial;
See the full eligibility criteria
- 1\. Aged 18-60 years at screening 2. Stable angina symptoms with suspected or confirmed coronary artery disease; 2. CCTA examination demonstrating: at least one major coronary artery with a diameter of ≥1.5mm that has...
- 3\. people who have been using statin therapy alone for at least 4 weeks prior to enrollment with a baseline LDL-C ≥1.8mmol/L or people who have not initiated lipid-lowering therapy prior to enrollment with a baseline...
- Left main coronary artery disease or severe three-vessel disease;
- Ultra-high-risk ASCVD patients: ≥2 severe ASCVD events or 1 severe ASCVD event with ≥2 high-risk factors;
- Use of PCSK9 inhibitors or ezetimibe within 8 weeks prior to study enrollment;
- The baseline LDL-C was relatively high (LDL-C≥2.6 mmol/L in those taking statins and ≥4.9 mmol/L in those not taking statins).
- Familial hypercholesterolemia;
- Known allergy/intolerance to lipid-lowering drugs used in the trial;
- Patients with severe congestive heart failure, liver or kidney dysfunction, or malignancy;
- Pregnant or breastfeeding female patients.
The study team makes the final eligibility decision.
Where it's taking place
- Chongqing, Chongqing Municipality, China
- Dongguan, Guangdong, China
- Guangzhou, Guangdong, China
- Shenzhen, Guangdong, China
- Zhongshan, Guangdong, China
- Dalian, Liaoning, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chongqing, Chongqing Municipality, China; Dongguan, Guangdong, China; Guangzhou, Guangdong, China; Shenzhen, Guangdong, China; Zhongshan, Guangdong, China; Dalian, Liaoning, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.